Cohance Lifesciences gains on receiving EIR from USFDA for API Unit-IV in Telangana

26 May 2025 Evaluate

Cohance Lifesciences is currently trading at Rs. 1094.55, up by 10.95 points or 1.01% from its previous closing of Rs. 1083.60 on the BSE.

The scrip opened at Rs. 1179.95 and has touched a high and low of Rs. 1179.95 and Rs. 1084.00 respectively. So far 2549 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1359.00 on 02-Dec-2024 and a 52 week low of Rs. 597.00 on 04-Jun-2024.

Last one week high and low of the scrip stood at Rs. 1179.95 and Rs. 1007.00 respectively. The current market cap of the company is Rs. 41762.94 crore.

The promoters holding in the company stood at 50.10%, while Institutions and Non-Institutions held 27.66% and 22.23% respectively.

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API Unit-IV, located at Plot No. A-21, Road No. 10, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, Telangana, India, from March 3, 2025 to March 7, 2025. 

The inspection was classified as Voluntary Action Indicated (VAI) and indicates the formal closure of the inspection process by the USFDA. The company remain committed to maintaining the highest standards of quality and regulatory compliance in all its operations.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.

Cohance Lifesciences Share Price

542.20 -6.90 (-1.26%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×